FI119812B - Menetelmä uusien, terapeuttisesti käyttökelpoisten peptidijohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien, terapeuttisesti käyttökelpoisten peptidijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI119812B
FI119812B FI955828A FI955828A FI119812B FI 119812 B FI119812 B FI 119812B FI 955828 A FI955828 A FI 955828A FI 955828 A FI955828 A FI 955828A FI 119812 B FI119812 B FI 119812B
Authority
FI
Finland
Prior art keywords
pab
cha
pro
hooc
aze
Prior art date
Application number
FI955828A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI955828A0 (fi
FI955828A (fi
Inventor
Ruth Elvy Bylund
Karl Thomas Antonsson
Nils David Gustafsson
Nils Olov Ingemar Nilsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of FI955828A0 publication Critical patent/FI955828A0/fi
Publication of FI955828A publication Critical patent/FI955828A/fi
Application granted granted Critical
Publication of FI119812B publication Critical patent/FI119812B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
FI955828A 1993-06-03 1995-12-04 Menetelmä uusien, terapeuttisesti käyttökelpoisten peptidijohdannaisten valmistamiseksi FI119812B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE19939301916A SE9301916D0 (sv) 1993-06-03 1993-06-03 New peptides derivatives
SE9301916 1993-06-03
SE9400535 1994-06-02
PCT/SE1994/000535 WO1994029336A1 (en) 1993-06-03 1994-06-02 New peptide derivatives

Publications (3)

Publication Number Publication Date
FI955828A0 FI955828A0 (fi) 1995-12-04
FI955828A FI955828A (fi) 1995-12-04
FI119812B true FI119812B (fi) 2009-03-31

Family

ID=20390165

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955828A FI119812B (fi) 1993-06-03 1995-12-04 Menetelmä uusien, terapeuttisesti käyttökelpoisten peptidijohdannaisten valmistamiseksi

Country Status (40)

Country Link
US (4) US5723444A (ja)
EP (2) EP1067136A1 (ja)
JP (3) JP3205558B2 (ja)
KR (1) KR100339456B1 (ja)
CN (2) CN1099425C (ja)
AT (1) ATE200783T1 (ja)
BR (1) BR9406746A (ja)
CA (1) CA2162900C (ja)
CZ (1) CZ290104B6 (ja)
DE (3) DE69427150T2 (ja)
DK (1) DK0701568T3 (ja)
EE (1) EE03264B1 (ja)
EG (1) EG20671A (ja)
ES (1) ES2128277T3 (ja)
FI (1) FI119812B (ja)
GR (1) GR3036258T3 (ja)
HK (1) HK1031375A1 (ja)
HR (1) HRP940311B1 (ja)
HU (2) HU226825B1 (ja)
IL (2) IL109634A (ja)
IS (1) IS1805B (ja)
LT (1) LT3768B (ja)
LU (1) LU91173I2 (ja)
MX (1) MX9404114A (ja)
MY (1) MY119155A (ja)
NL (1) NL300178I2 (ja)
NO (2) NO314406B1 (ja)
NZ (1) NZ267534A (ja)
PL (1) PL181968B1 (ja)
PT (1) PT701568E (ja)
RS (1) RS49576B (ja)
RU (1) RU2142469C1 (ja)
SA (1) SA94150051B1 (ja)
SE (1) SE9301916D0 (ja)
SG (1) SG48013A1 (ja)
SI (1) SI0701568T1 (ja)
SK (1) SK283150B6 (ja)
TW (1) TW403731B (ja)
UA (1) UA65518C2 (ja)
WO (1) WO1994029336A1 (ja)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9900043D0 (sv) * 1999-01-11 1999-01-11 Astra Ab New use
CN1077886C (zh) * 1993-10-21 2002-01-16 G·D·瑟尔公司 用作一氧化一氮合酶抑制剂的脒基衍生物
JP4561696B2 (ja) * 1994-01-27 2010-10-13 三菱化学株式会社 プロリンアミド誘導体
ZA951618B (en) * 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
CA2143533A1 (en) * 1994-03-04 1995-09-05 Kenneth D. Kurz Antithrombotic agents
US5885967A (en) * 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5602101A (en) * 1994-03-04 1997-02-11 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
AU2790895A (en) * 1994-06-10 1996-01-05 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
CA2210989A1 (en) * 1995-02-10 1996-08-15 Basf Aktiengesellschaft Thrombin inhibitors
NZ302649A (en) * 1995-02-17 2000-01-28 Basf Ag Dipeptide amidine derivatives, preparation and pharmaceutical compositions thereof
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5629324A (en) * 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
US5610308A (en) * 1995-05-18 1997-03-11 Bristol-Myers Squibb Company Process for preparing intermediates for thrombin inhibitors
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
CA2227607C (en) * 1995-07-26 2008-06-10 Mitsubishi Chemical Corporation Penicillaminamide derivatives
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
TW455580B (en) * 1995-12-09 2001-09-21 Roche Diagnostics Gmbh 3-aminoethyl-N-amidino-2,5-dihyropyrrole-derivatives having arginine mimentic properties and pharmaceutical compositions containing these compounds
GB9526273D0 (en) * 1995-12-21 1996-02-21 Astra Ab New prodrugs
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9600216D0 (sv) * 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
EP1007544A1 (en) * 1996-02-13 2000-06-14 Akzo Nobel N.V. Serine protease inhibitors
TW523513B (en) * 1996-03-01 2003-03-11 Akzo Nobel Nv Serine protease inhibitors
IL120310A (en) * 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
US5811402A (en) * 1996-03-22 1998-09-22 Eli Lilly And Company Antithrombotic diamides
SE9602145D0 (sv) * 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
US6200967B1 (en) 1996-06-25 2001-03-13 Eli Lilly And Company Anticoagulant agents
US5863929A (en) * 1996-06-25 1999-01-26 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
US6756389B2 (en) * 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US5792761A (en) * 1996-08-12 1998-08-11 Merck & Co., Inc. Thrombin inhibitors
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
DE19632773A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
IL121474A0 (en) * 1996-08-23 1998-02-08 Akzo Nobel Nv Thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
US5869487A (en) * 1996-10-24 1999-02-09 Merck & Co., Inc. Pyrido 3,4-B!pyrazines for use as thrombin inhibitors
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
US6740682B2 (en) 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
DE69830410T2 (de) * 1997-08-29 2006-01-26 Tularik Ltd. Meta-benzamidinderivate als serinprotease-inhibitoren
US6087373A (en) * 1997-09-23 2000-07-11 Merck & Co., Inc. Thrombin inhibitors
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
DE19755682A1 (de) * 1997-12-15 1999-06-17 Knoll Ag Verfahren zur Ermittlung eines Dosierungschemas für Thrombininhibitoren
WO1999037611A1 (de) * 1998-01-26 1999-07-29 Basf Aktiengesellschaft Heterocyclische amidine als kallikrein protease inhibitoren
CA2317761A1 (en) 1998-01-26 1999-07-29 Basf Aktiengesellschaft Thrombin inhibitors
US6417161B1 (en) 1998-04-24 2002-07-09 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
SE9802939D0 (sv) 1998-09-01 1998-09-01 Astra Ab New process
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
KR20000047461A (ko) * 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
WO2000042059A1 (en) 1999-01-13 2000-07-20 Astrazeneca Ab New amidinobenzylamine derivatives and their use as thrombin inhibitors
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
WO2000061608A2 (de) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Niedermolekulare inhibitoren von komplementproteasen
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
DE50008187D1 (de) * 1999-05-10 2004-11-18 Abbott Gmbh & Co Kg Salze von Thrombininhibitoren
JP2003501389A (ja) 1999-06-04 2003-01-14 メルク エンド カムパニー インコーポレーテッド トロンビン阻害物質
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
CA2383358A1 (en) * 1999-08-31 2001-03-08 Board Of Regents, The University Of Texas System Methods and compositions of a novel serine protease inhibitor
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
DE10029015A1 (de) * 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6528503B2 (en) 2000-12-18 2003-03-04 Merck & Co., Inc. Thrombin inhibitors
AU2002230836A1 (en) 2000-12-18 2002-07-01 Merck & Co., Inc. Benzylamine derivatives and their use as thrombin inhibitors
US7144899B2 (en) 2001-02-09 2006-12-05 Merck & Co., Inc. Thrombin inhibitors
DE10117730A1 (de) 2001-04-09 2002-10-10 Basf Ag Umsetzung von (Di)Aminen in Gegenwart einer Lysinoxidase und eines Reduktionsmittels
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
SE0103590D0 (sv) 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
DE10210590A1 (de) * 2002-03-11 2003-10-02 Curacyte Ag Hemmstoffe des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
US7838560B2 (en) 2002-03-11 2010-11-23 The Medicines Company (Leipzig) Gmbh Urokinase inhibitors, production and use thereof
US7084134B2 (en) 2002-05-02 2006-08-01 Merk & Co., Inc. Thrombin inhibitors
ES2316770T3 (es) 2002-05-21 2009-04-16 Mayo Foundation For Medical Education And Research Procedimiento y materiales para el tratamiento y diagnostico de afecciones inflamatorias relacionadas con kalicreina-6.
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0301879D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Ab New process
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
FR2867780B1 (fr) * 2004-03-19 2006-05-19 Servier Lab Nouveaux derives de 4-oxo-4,6,7,8-tetrahydropyrrolo (1,2-a) pyrazine-6-carboxamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005095327A1 (ja) 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
US7795205B2 (en) 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
US20060194325A1 (en) * 2005-02-14 2006-08-31 Gable Jennifer H Fluid handling cassette with a fluid control interface
JP2008540372A (ja) * 2005-05-03 2008-11-20 バイエル・クロツプサイエンス・エス・アー 新規ヘテロシクリルエチルアミド誘導体
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
CA2644926A1 (en) * 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin and fibrinogen
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
GB0807828D0 (en) * 2008-04-29 2008-06-04 Vantia Ltd Aminopyridine derivatives
CN102924567B (zh) * 2008-10-28 2014-06-04 上海医药工业研究院 一类肽化合物、其制备方法及用途
US20110165279A1 (en) * 2010-01-06 2011-07-07 Academia Sinica Office of Public Affairs (Technology Licensing) Sweet potato trypsin inhibitor and methods for treating inflammation and hyperalgesia
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
WO2012075287A2 (en) * 2010-12-01 2012-06-07 The University Of Mississippi Novel selective inhibitors of prolylcarboxypeptidase
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
WO2019231935A1 (en) * 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
WO2021113686A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
CA3159167A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748295A1 (de) * 1977-10-27 1979-05-03 Bayer Ag Neue derivate des bpti
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
US4568636A (en) * 1981-03-25 1986-02-04 Pentapharm Ag Tripeptide derivatives
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3505555A1 (de) * 1985-02-18 1986-09-11 Behringwerke Ag, 3550 Marburg Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE3606480A1 (de) * 1986-02-28 1987-09-03 Behringwerke Ag Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5037819A (en) * 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US5110812A (en) * 1990-06-04 1992-05-05 Bristol-Myers Squibb Co. Azetidin-2-one derivatives as serine protease inhibitors
TW201303B (ja) 1990-07-05 1993-03-01 Hoffmann La Roche
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
IL99527A (en) * 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
EP0511347A1 (de) * 1990-11-15 1992-11-04 Pentapharm A.G. Meta-substituierte phenylalanin-derivate
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
NZ245039A (en) * 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
CA2140598C (en) * 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
SE504185C2 (sv) * 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors

Also Published As

Publication number Publication date
IL109634A0 (en) 1994-08-26
YU33694A (sh) 1997-12-05
GR3036258T3 (en) 2001-10-31
EP0701568A1 (en) 1996-03-20
SI0701568T1 (en) 2001-08-31
US5939392A (en) 1999-08-17
IS1805B (is) 2002-03-08
UA65518C2 (en) 2004-04-15
DE69427150D1 (de) 2001-05-31
HU0103039D0 (en) 2001-09-28
EG20671A (en) 1999-11-30
NO954873L (no) 1996-02-01
DE69427150T2 (de) 2001-09-06
MY119155A (en) 2005-04-30
KR100339456B1 (ko) 2002-12-06
SK145495A3 (en) 1996-10-02
SG48013A1 (en) 1998-04-17
NO2004009I1 (no) 2004-12-20
HU226825B1 (en) 2009-11-30
JP2001322974A (ja) 2001-11-20
SE9301916D0 (sv) 1993-06-03
PL311819A1 (en) 1996-03-18
DE122004000045I2 (de) 2011-06-16
CZ290104B6 (cs) 2002-05-15
CA2162900A1 (en) 1994-12-22
CN1278530A (zh) 2001-01-03
CA2162900C (en) 2009-06-09
HUT74739A (en) 1997-02-28
CN1127509A (zh) 1996-07-24
LT3768B (en) 1996-03-25
NO314406B1 (no) 2003-03-17
SA94150051B1 (ar) 2006-06-12
US5723444A (en) 1998-03-03
NZ267534A (en) 1997-08-22
JPH08511018A (ja) 1996-11-19
RU2142469C1 (ru) 1999-12-10
FI955828A0 (fi) 1995-12-04
HRP940311A2 (en) 1996-10-31
MX9404114A (es) 1995-01-31
EP1067136A1 (en) 2001-01-10
JP3205558B2 (ja) 2001-09-04
IL109634A (en) 1999-04-11
HRP940311B1 (en) 2002-02-28
AU6986994A (en) 1995-01-03
CZ302095A3 (en) 1996-04-17
DK0701568T3 (da) 2001-06-18
DE701568T1 (de) 1999-06-02
NL300178I1 (nl) 2005-05-02
ES2128277T3 (es) 2001-07-01
BR9406746A (pt) 1996-03-19
PT701568E (pt) 2001-08-30
ATE200783T1 (de) 2001-05-15
IS4166A (is) 1994-12-04
CN1099425C (zh) 2003-01-22
PL181968B1 (pl) 2001-10-31
US20050222395A1 (en) 2005-10-06
WO1994029336A1 (en) 1994-12-22
HK1031375A1 (en) 2001-06-15
IL123996A (en) 2008-07-08
ES2128277T1 (es) 1999-05-16
HU9503445D0 (en) 1996-01-29
CN1178905C (zh) 2004-12-08
AU684086B2 (en) 1997-12-04
EE03264B1 (et) 2000-04-17
EP0701568B1 (en) 2001-04-25
JP2002047264A (ja) 2002-02-12
DE122004000045I1 (de) 2005-04-21
SK283150B6 (sk) 2003-03-04
TW403731B (en) 2000-09-01
NO954873D0 (no) 1995-11-30
RS49576B (sr) 2007-04-10
US5602253A (en) 1997-02-11
FI955828A (fi) 1995-12-04
LU91173I2 (fr) 2005-07-11
LTIP1947A (en) 1994-12-27
NL300178I2 (nl) 2005-10-03

Similar Documents

Publication Publication Date Title
FI119812B (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten peptidijohdannaisten valmistamiseksi
US5780631A (en) Starting materials in the synthesis of thrombin and kininogenase inhibitors
JP3453357B2 (ja) トロンビンの阻害剤および基質
US5955433A (en) Method of thrombin inhibition
US6337343B1 (en) Amino acid derivatives
US6984627B1 (en) Peptide derivatives
AU709088B2 (en) Thrombin inhibitors
JPS5951246A (ja) 置換ペプチド化合物
US6774110B2 (en) Orally available peptidic thrombin inhibitors
EP0832879A1 (en) Process for preparing intermediates for thrombin inhibitors
AU684086C (en) New peptide derivatives
AU3659200A (en) Prodrugs of thrombin inhibitors

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119812

Country of ref document: FI